Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Wrong Labelling: Intas...

    Wrong Labelling: Intas Pharma US arm recalls over 46,000 bottles of diuretic drug

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-24T12:38:23+05:30  |  Updated On 24 Sept 2018 12:38 PM IST
    Wrong Labelling: Intas Pharma US arm recalls over 46,000 bottles of diuretic drug
    Accord Healthcare recall is based on "Labelling: label mix-up: customer complaint that a sealed bottle labelled as Hydrochlorothiazide tablets USP 12.5 mg contained only Spironolactone tablets USP 25 mg,"

    New Delhi: Accord Healthcare Inc, the US arm of Intas Pharmaceuticals, is recalling over 46,000 bottles of Hydrochlorothiazide tablets manufactured by the Ahmedabad-based firm, on account of labelling mix-up, USFDA said. Intas Pharmaceuticals Ltd. through its wholly-owned subsidiary Accord Healthcare Ltd.


    Hydrochlorothiazide tablets belong to a class of drugs known as diuretics and are used for the treatment of high blood pressure and edema.


    Accord Healthcare is recalling 46,632 bottles of Hydrochlorothiazide tablets USP in the strength of 12.5 mg, the Enforcement Report by United States Food and Drug Administration (USFDA) said.

    The reason for the recall is "Labelling: label mix-up: customer complaint that a sealed bottle labelled as Hydrochlorothiazide tablets USP 12.5 mg contained only Spironolactone tablets USP 25 mg," it added.

    The voluntary nationwide recall in the US and Puerto Rico has not been classified yet, the report said.

    Read Also: Intas Pharmaceuticals Completes Deal to Acquire Actavis UK, Ireland Generics Businesses From Teva
    AccordAccord HealthcareAccord Healthcare IncAhmedabadblood pressurediureticsedemaHydrochlorothiazide tabletsIntas PharmaLabelling: label mix-upUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok